HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Enthusiasm for IORT in breast cancer tempered by trial designs, recurrence rates
• Physician groups support proposed FDA biosimilar naming convention, but also call for maker ID
• Given high stakes of cancer care, biosimilar debate requires an open mind John Sweetenham, MD, FRCP, FACP
• FDA approves Imlygic for unresectable melanoma
• FDA expands Yervoy approval to include adjuvant treatment of stage III melanoma
• FDA approves Cotellic as part of combination regimen for advanced melanoma
• FDA grants breakthrough therapy designation to Keytruda for advanced colorectal cancer
• FDA grants pexidartinib breakthrough therapy designation for tenosynovial giant cell tumor
• FDA issues order to stop sale of 4 R.J. Reynolds cigarette brands
• Sickle cell trait may increase risk for renal disease in blacks
• ASCO updates guideline on treatment of advanced NSCLC
• Bisphosphonates improve breast cancer survival in postmenopausal women
• BRCA testing has 'clear role' for triple-negative breast cancer
• Childhood cancer survivors likely to need federal income assistance as adults
• Clinical trial data may not apply to real-world patients with kidney cancer
• Clonal hematopoiesis common, variable in patients with aplastic anemia
• Common erectile dysfunction medication may increase melanoma risk
• Despite recommendations, some patients with early-stage, asymptomatic NSCLC undergo brain imaging
• Ethanol locks reduce central venous catheter-associated bloodstream infections in children with cancer
• Extended-field IMRT does not increase duodenal toxicity in gynecologic cancers
• Gene assay identifies women who can be spared chemotherapy for breast cancer
• Genetic expression may predict metastases risk, OS in Ewing’s sarcoma
• Genomic data may better classify lower-grade glioma than histology
• Haploidentical donor HSCT may confer similar outcomes to matched, related donors
• Hormone replacement therapy increases risk for ovarian cancer
• IV immune globulin temporarily increases thromboembolic risks in CLL, multiple myeloma
• Long-term data clarify role of adjuvant radiotherapy after lymphadenectomy for melanoma
• Low PSA levels may predict aggressive prostate cancer higher mortality risk
• Mammography screening associated with increase in small breast cancers
• Many older patients with early-stage breast cancer receive radiation despite limited effectiveness
• Military protocol may benefit civilians in need of massive blood transfusion
• Most blood clot treatments demonstrate similar efficacy, safety
• Multigene panel testing can alter risk assessment, management for BRCA-negative women
• Novel agent shows promise in treatment of rare joint neoplasm
• One-third of patients do not receive recommended post-mastectomy radiation
• Precision medicine techniques show promise for pediatric patients with relapsed, refractory cancer
• Sickle cell disease increases mortality risk during pregnancy
• Some long-term survivors of low-grade glioma experience decline in health-related quality of life
• Spousal mood impacts risk for depressed mood in cancer survivors
• Toxicity may limit use of ponatinib for first-line treatment of CML
• Vitamin D, calcium do not reduce risk for colorectal adenomas
• Voriconazole increases risk for squamous cell carcinoma, reduces Aspergillus colonization
• VTE risk assessment model validated for critically ill surgical patients
• Younger women, black women face greater risk for mortality after DCIS
• Addario Lung Cancer Foundation presents lectureship award
• ASH elects three to executive committee
• ASTRO names 2015 honorary member
• City of Hope names medical director for clinical research operations
• Fox Chase Cancer Center appoints attending physician
• Medical oncologist joins cancer center
• Penn appoints chair of department of cell and developmental biology
• Professor to lead joint pediatric hematology/oncology program
• Rutgers Cancer Institute of New Jersey appoints thoracic oncology chief
• 18F-fluorodeoxyglucose PET/CT evaluations for multiple myeloma lack standardization
• African Americans at higher risk for pancreatic cancer at younger age
• Circulating melanoma cells predict relapse in stage III disease
• Coexisting BRAF, TERT mutations predict poorer survival in papillary thyroid cancer
• Combination of signal target molecule inhibitors shows promise for CLL treatment
• C-reactive protein predicted prognosis in metastatic colorectal cancer
• Daily anti-androgen therapy improves survival for patients with recurrent prostate cancer
• Deletion 17p predicts poor outcomes in newly diagnosed myeloma regardless of induction, ASCT
• Dexamethasone reduces radiation-induced pain flare among patients with bone metastases
• Diabetes, metabolic syndrome increase risk for HCC
• EQUIP-3: Endoscopic quality improvement program increases ADR
• FMT via colonoscopy bests placebo for preventing recurrent C. difficile
• Genetic variants common, predictive in poorly differentiated, anaplastic thyroid cancers
• Ibrutinib demonstrates long-term effectiveness in previously treated CLL
• Ibrutinib–dexamethasone combination effective in relapsed, refractory myeloma
• Ibrutinib induces durable responses in CLL
• Idelalisib, ibrutinib combination regimens beneficial in relapsed/refractory CLL
• Image-guided IMRT for cervical cancer may reduce late bowel effects
• Immune checkpoint inhibitors show promise for treatment of lymphomas
• Immune surveillance may predict therapy response in medullary thyroid cancer
• Indolent, aggressive papillary thyroid microcarcinomas have distinct molecular profiles
• Ipilimumab plus radiotherapy may benefit patients with metastatic melanoma
• Limited resection in CRC puts young patients at risk for recurrence
• Men’s health supplements fail to improve prostate cancer outcomes
• Optune plus temozolomide extended survival in glioblastoma
• Ovarian suppression during chemotherapy may prevent infertility in women with breast cancer
• Overcrowded households, gender may affect incidence of Hodgkin’s lymphoma subtypes
• Paclitaxel may serve as standard treatment for anaplastic thyroid carcinoma
• Pomalidomide plus low-dose dexamethasone shows promise for relapsed, refractory multiple myeloma
• Reduced-intensity chemoradiotherapy safe, effective for HPV-related oropharynx cancer
• Risks of adjuvant WBRT may outweigh benefits for limited brain metastases
• Shorter-course radiation noninferior to conventional therapy for low-risk prostate cancer
• TERT copy number, methylation hold prognostic value for medullary thyroid carcinoma
• Top Takeaways from ASCO: Brain metastases and genetic profiles
• Top Takeaways from ASCO: Childhood Cancer Survivor Study and smoking interventions
• Top Takeaways from ASCO: Esophageal cancer
• Top Takeaways from ASCO: Gynecologic cancers and sexual dysfunction
• Top Takeaways from ASCO: Lung cancer
• Top Takeaways from ASCO: Male breast cancer
• Variety of stents similar in cost-effectiveness for pancreatic adenocarcinoma
• Ovarian suppression plus tamoxifen reduced breast cancer recurrence in high-risk premenopausal women
• Anthracycline-based chemotherapy leads to diastolic dysfunction in many patients with breast cancer